Bilimsel çalışmalar

Doç. Dr. Heves Sürmeli

48 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

    Clinical Medicine Insights Oncology, 2026

    DOI 10.1177/11795549261445290 PMID 42131419 Açık erişimli tam metinKaynak: OpenAlex

  2. Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16037-8 PMID 41987096 Açık erişimli tam metinKaynak: OpenAlex

  3. Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15010386 PMID 41517635 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  4. Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

    Journal of Cancer Research and Clinical Oncology, 2026

    DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  5. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15051853 PMID 41827267 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  6. Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

    Medicina, 2026

    DOI 10.3390/medicina62010099 PMID 41597386 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  7. Pan‑immune‑inflammation value as a prognostic and predictive biomarker in metastatic non‑small cell lung cancer treated with nivolumab: A real‑world study

    Oncology Letters, 2026

    DOI 10.3892/ol.2026.15750 PMID 42491228 Açık erişimli tam metinKaynak: ORCID

  8. Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study

    Cancer Control, 2026

    DOI 10.1177/10732748261432273 PMID 41779425 Açık erişimli tam metinKaynak: ORCID

  9. Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf054 PMID 40271640 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  10. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14197103 PMID 41096183 4 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  11. Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study

    Journal of Personalized Medicine, 2025

    DOI 10.3390/jpm16010008 PMID 41590501 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  12. Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

    Medicina, 2025

    DOI 10.3390/medicina61050819 PMID 40428777 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  13. Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

    Medicina, 2025

    DOI 10.3390/medicina61071161 PMID 40731791 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  14. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  15. Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer

    Pharmaceuticals, 2025

    DOI 10.3390/ph18060931 PMID 40573326 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  16. Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy

    Current Oncology, 2025

    DOI 10.3390/curroncol32090503 PMID 41002573 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  17. Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study

    Acta haematologica oncologica Turcica., 2025

    DOI 10.4274/ahot.galenos.2025.2025-1-1 Açık erişimli tam metinKaynak: OpenAlex

  18. Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment

    Cancers, 2025

    DOI 10.3390/cancers17071076 PMID 40227569 Açık erişimli tam metinKaynak: OpenAlex

  19. Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)

    Healthcare, 2025

    DOI 10.3390/healthcare13151810 PMID 40805843 Açık erişimli tam metinKaynak: OpenAlex

  20. Association Between Prognostic Nutritional Index and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25030 Açık erişimli tam metinKaynak: OpenAlex

  21. Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61010154 PMID 39859134 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  22. The Effect of Concomitant Metformin Use on Progression-Free and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

    2025

    DOI 10.20944/preprints202506.0074.v1 Açık erişimli tam metinKaynak: ORCID

  23. The Potential Synergistic Effects of Metformin and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer

    Southern Clinics of Istanbul Eurasia, 2025

    DOI 10.14744/scie.2025.65768 Açık erişimli tam metinKaynak: OpenAlex

  24. Impact of Progression Sites and Line of Therapy on Survival Outcomes in Patients with Her-2 Positive Metastatic Breast Cancer Treated with T-DM1

    Northern Clinics of Istanbul, 2025

    DOI 10.14744/nci.2025.48902 PMID 41059432 Açık erişimli tam metinKaynak: OpenAlex

  25. EP.14.06 Survival Analysis in Malignant Pleural Mesothelioma

    Journal of Thoracic Oncology, 2025

    DOI 10.1016/j.jtho.2025.09.1650 Açık erişimli tam metinKaynak: OpenAlex

  26. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-63096-7 PMID 38802494 21 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  27. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

    Medicina, 2024

    DOI 10.3390/medicina60081374 PMID 39202654 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  28. A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

    Cancers, 2024

    DOI 10.3390/cancers16142512 PMID 39061152 5 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  29. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    Journal of Clinical Medicine, 2024

    DOI 10.3390/jcm13206263 PMID 39458213 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  30. Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?

    Medicina, 2024

    DOI 10.3390/medicina60081372 PMID 39202652 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  31. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-World Study

    Medicina, 2024

    DOI 10.3390/medicina60071088 PMID 39064516 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  32. Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression

    Medicina, 2024

    DOI 10.3390/medicina60122069 PMID 39768949 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  33. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy

    Cureus, 2024

    DOI 10.7759/cureus.63362 PMID 39070363 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  34. Association of New Inflammatory Markers Cumulative Inflammatory Index (ICC) and Mean Corpuscular Volume/Lymphocyte (MCVL) with Anti PD-1 Antibody Nivolumab Treatment Response in Metastatic Renal Cell Carcinoma

    Research Square, 2024

    DOI 10.21203/rs.3.rs-5381728/v1 Açık erişimli tam metinKaynak: OpenAlex

  35. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    2024

    DOI 10.20944/preprints202409.0812.v1 Açık erişimli tam metinKaynak: ORCID

  36. Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience

    World journal of urology, 2023

    DOI 10.1007/s00345-023-04482-0 PMID 37351618 3 atıf (Europe PMC) Kaynak: Europe PMC

  37. Sarkomlar ve Cilt Tümörleri

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1097 Açık erişimli tam metinKaynak: OpenAlex

  38. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211015762 PMID 33961521 10 atıf (Europe PMC) Açık erişimli tam metinKaynak: OpenAlex

  39. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient?

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211038136 PMID 34558355 1 atıf (Europe PMC) Kaynak: OpenAlex

  40. Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/1078155220924088 PMID 32423326 8 atıf (Europe PMC) Kaynak: ORCID

  41. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?

    Current Problems in Cancer, 2020

    DOI 10.1016/j.currproblcancer.2020.100670 PMID 33129567 1 atıf (Europe PMC) Kaynak: OpenAlex

  42. Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer

    Turkish journal of obstetrics and gynecology, 2020

    DOI 10.4274/tjod.galenos.2020.90699 PMID 32850187 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

  43. Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients

    Tumor Biology, 2016

    DOI 10.1007/s13277-015-4776-1 PMID 26753955 11 atıf (Europe PMC) Kaynak: OpenAlex

  44. Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma

    Clinical Colorectal Cancer, 2016

    DOI 10.1016/j.clcc.2016.04.013 PMID 27247089 17 atıf (Europe PMC) Kaynak: OpenAlex

  45. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy

    Clinical & Translational Oncology, 2015

    DOI 10.1007/s12094-015-1283-1 PMID 25786367 23 atıf (OpenAlex) Kaynak: OpenAlex

  46. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

    Clinical & Translational Oncology, 2015

    DOI 10.1007/s12094-015-1408-6 PMID 26459249 3 atıf (OpenAlex) Kaynak: OpenAlex

  47. Three Different Chemotherapy Combinations with Concurrent Thoracic Radiation for Patients with Stage III Non-Small Cell Lung Cancer

    Annals of Oncology, 2014

    DOI 10.1093/annonc/mdu348.10 Açık erişimli tam metinKaynak: OpenAlex

  48. Approach to mushroom intoxication and treatment: Can we decrease mortality?

    Clinics and Research in Hepatology and Gastroenterology, 2011

    DOI 10.1016/j.clinre.2011.11.004 PMID 22189510 33 atıf (OpenAlex) Kaynak: OpenAlex